During the follow-up period, 17 patients (22.7%) had disease progression (7 cases of Her2-positive BC, 5 cases of luminal/HER2-positive BC, 2 cases of luminal/HER2-positive BC, 3 cases of TNBC); among them, 1 case was from the pCR group, and 16 cases were from the Non-pCR group. The gene discussed is ERBB2; the disease is breast cancer.